Women’s Health Bulletin

Published by: Kowsar

Changes of Bladder Function Related to the Effects of Menopause

Keon-Cheol Lee 1 , *
Author Information
1 Department of Urology, Inje University School of Medicine, Ilsanpaik Hospital, Goyang, Korea
Article information
  • Women’s Health Bulletin: April 2018, 5 (2); e14390
  • Published Online: December 10, 2017
  • Article Type: Review Article
  • Received: April 10, 2017
  • Revised: May 31, 2017
  • Accepted: August 8, 2017
  • DOI: 10.5812/whb.14390

How to Cite: Lee K. Changes of Bladder Function Related to the Effects of Menopause, Women Health Bull. 2018 ; 5(2):e14390. doi: 10.5812/whb.14390.

Copyright © 2017, Women’s Health Bulletin. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Postmenopausal Bladder Function
2. Ovariectomized Animals in an Experimental Menopause Model
3. Possible Mechanisms of OAB After Menopause
4. Can Hormone Replacement Reverse OAB?
  • 1. Robinson D, Toozs-Hobson P, Cardozo L. The effect of hormones on the lower urinary tract. Menopause Int. 2013;19(4):155-62. doi: 10.1177/1754045313511398. [PubMed: 24336244].
  • 2. Thomas TM, Plymat KR, Blannin J, Meade TW. Prevalence of urinary incontinence. Br Med J. 1980;281(6250):1243-5. [PubMed: 7427654].
  • 3. Quinn SD, Domoney C. The effects of hormones on urinary incontinence in postmenopausal women. Climacteric. 2009;12(2):106-13. doi: 10.1080/13697130802630083. [PubMed: 19259853].
  • 4. Waetjen LE, Johnson WO, Xing G, Feng WY, Greendale GA, Gold EB, et al. Serum estradiol levels are not associated with urinary incontinence in midlife women transitioning through menopause. Menopause. 2011;18(12):1283-90. doi: 10.1097/gme.0b013e31821f5d25. [PubMed: 21785372].
  • 5. Gopal M, Sammel MD, Arya LA, Freeman EW, Lin H, Gracia C. Association of change in estradiol to lower urinary tract symptoms during the menopausal transition. Obstet Gynecol. 2008;112(5):1045-52. doi: 10.1097/AOG.0b013e31818b4cad. [PubMed: 18978104].
  • 6. Teleman PM, Persson J, Mattiasson A, Samsioe G. The relation between urinary incontinence and steroid hormone levels in perimenopausal women. A report from the Women's Health in the Lund Area (WHILA) study. Acta Obstet Gynecol Scand. 2009;88(8):927-32. doi: 10.1080/00016340903117986. [PubMed: 19579140].
  • 7. Legendre G, Ringa V, Fauconnier A, Fritel X. Menopause, hormone treatment and urinary incontinence at midlife. Maturitas. 2013;74(1):26-30. doi: 10.1016/j.maturitas.2012.10.005. [PubMed: 23141079].
  • 8. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21(1):5-26. doi: 10.1007/s00192-009-0976-9. [PubMed: 19937315].
  • 9. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306-14. discussion 1314-5. doi: 10.1016/j.eururo.2006.09.019. [PubMed: 17049716].
  • 10. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327-36. doi: 10.1007/s00345-002-0301-4. [PubMed: 12811491].
  • 11. Juliato CR, Baccaro LF, Pedro AO, Costa-Paiva L, Lui-Filho J, Pinto-Neto AM. Subjective urinary urgency in middle age women: A population-based study. Maturitas. 2016;85:82-7. doi: 10.1016/j.maturitas.2015.12.009. [PubMed: 26857885].
  • 12. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87(9):760-6. [PubMed: 11412210].
  • 13. Bartoli S, Aguzzi G, Tarricone R. Impact on quality of life of urinary incontinence and overactive bladder: a systematic literature review. Urology. 2010;75(3):491-500. doi: 10.1016/j.urology.2009.07.1325. [PubMed: 19962738].
  • 14. Chiaffarino F, Parazzini F, Lavezzari M, Giambanco V. Impact of urinary incontinence and overactive bladder on quality of life. Europ Urol. 2003;43(5):535-8.
  • 15. Speroff L. The perimenopause: definitions, demography, and physiology. Obstet Gynecol Clinic North America. 2002;29(3):397-410.
  • 16. Fantl JA. The lower urinary tract in women—effect of aging and menopause on continence. Experiment Gerontol. 1994;29(3):417-22.
  • 17. Sturdee DW, Panay N, International Menopause Society Writing G. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010;13(6):509-22. doi: 10.3109/13697137.2010.522875. [PubMed: 20883118].
  • 18. Chen Y, Yu W, Yang Y, Duan J, Xiao Y, Zhang X, et al. Association between overactive bladder and peri-menopause syndrome: a cross-sectional study of female physicians in China. Int Urol Nephrol. 2015;47(5):743-9. doi: 10.1007/s11255-015-0948-6. [PubMed: 25838031].
  • 19. Zhu L, Cheng X, Sun J, Lv S, Mei S, Chen X, et al. Association between Menopausal Symptoms and Overactive Bladder: A Cross-Sectional Questionnaire Survey in China. PLoS One. 2015;10(10). e0139599. doi: 10.1371/journal.pone.0139599. [PubMed: 26448626].
  • 20. Vieira-Baptista P, Marchitelli C, Haefner HK, Donders G, Perez-Lopez F. Deconstructing the genitourinary syndrome of menopause. Int Urogynecol J. 2017;28(5):675-9. doi: 10.1007/s00192-017-3295-6. [PubMed: 28293790].
  • 21. Lee KC. Changes of muscarinic receptors and connexin-43 expression as a mechanism of overactive bladder in ovariectomized rats. World J Urol. 2015;33(11):1875-9. doi: 10.1007/s00345-015-1496-5. [PubMed: 25647175].
  • 22. Matthews KA, Abrams B, Crawford S, Miles T, Neer R, Powell LH, et al. Body mass index in mid-life women: relative influence of menopause, hormone use, and ethnicity. Int J Obes Relat Metab Disord. 2001;25(6):863-73. doi: 10.1038/sj.ijo.0801618. [PubMed: 11439301].
  • 23. McGrother CW, Donaldson MM, Hayward T, Matthews R, Dallosso HM, Hyde C, et al. Urinary storage symptoms and comorbidities: a prospective population cohort study in middle-aged and older women. Age Ageing. 2006;35(1):16-24. doi: 10.1093/ageing/afi205. [PubMed: 16234314].
  • 24. Trémollières FA, Pouilles JM, Cauneille C, Ribot C. Coronary heart disease risk factors and menopause: a study in 1684 French women. Atheroscl. 1999;142(2):415-23.
  • 25. Lai H, Gardner V, Vetter J, Andriole GL. Correlation between psychological stress levels and the severity of overactive bladder symptoms. BMC Urol. 2015;15:14. doi: 10.1186/s12894-015-0009-6. [PubMed: 25887525].
  • 26. Liu RT, Chung MS, Lee WC, Chang SW, Huang ST, Yang KD, et al. Prevalence of overactive bladder and associated risk factors in 1359 patients with type 2 diabetes. Urology. 2011;78(5):1040-5. doi: 10.1016/j.urology.2011.05.017. [PubMed: 21958505].
  • 27. Diep N, Constantinou CE. Age dependent response to exogenous estrogen on micturition, contractility and cholinergic receptors of the rat bladder. Life Scie. 1999;64(23):PL279-89.
  • 28. Lee KS, Na YG, Dean-McKinney T, Klausner AP, Tuttle JB, Steers WD. Alterations in voiding frequency and cystometry in the clomipramine induced model of endogenous depression and reversal with fluoxetine. J Urol. 2003;170(5):2067-71. doi: 10.1097/01.ju.0000080648.01911.9a. [PubMed: 14532855].
  • 29. Breyer BN, Wang G, Lin G, Shindel AW, Yang R, Lin CS, et al. The effect of long-term hormonal treatment on voiding patterns during filling cystometry and on urethral histology in a postpartum, ovariectomized female rat. BJU Int. 2010;106(11):1775-81. doi: 10.1111/j.1464-410X.2010.09268.x. [PubMed: 20201831].
  • 30. Patra PB, Thorneloe KS, Laping NJ. Effect of estrogen and progesterone on urodynamics in the conscious rat. Urology. 2009;74(2):463-6. doi: 10.1016/j.urology.2008.12.046. [PubMed: 19573897].
  • 31. Bujok J, Wincewicz E, Czerski A, Zawadzki W. Influence of ovariohysterectomy and deslorelin acetate on the spontaneous activity of the rabbit urinary bladder in vitro. Theriogenology. 2016;85(3):441-6. doi: 10.1016/j.theriogenology.2015.09.018. [PubMed: 26474688].
  • 32. Liang W, Afshar K, Stothers L, Laher I. The influence of ovariectomy and estrogen replacement on voiding patterns and detrusor muscarinic receptor affinity in the rat. Life Sci. 2002;71(3):351-62.
  • 33. Long CY, Liu CM, Hsu SC, Chen YH, Wu CH, Tsai EM. A randomized comparative study of the effects of oral and topical estrogen therapy on the lower urinary tract of hysterectomized postmenopausal women. Fertil Steril. 2006;85(1):155-60. doi: 10.1016/j.fertnstert.2005.06.042. [PubMed: 16412747].
  • 34. Juan YS, Chuang SM, Long CY, Chen CH, Levin RM, Liu KM, et al. Neuroprotection of green tea catechins on surgical menopause-induced overactive bladder in a rat model. Menopause. 2012;19(3):346-54. doi: 10.1097/gme.0b013e31822d652d. [PubMed: 22042325].
  • 35. Long CY, Hsu CS, Shao PL, Liu CM, Su JH, Tsai EM. Effect of ovariectomy on the gene expression of detrusor muscarinic receptors in female rats. Fertil Steril. 2009;92(3):1147-9. doi: 10.1016/j.fertnstert.2009.01.161. [PubMed: 19328480].
  • 36. Neuhaus J, Weimann A, Stolzenburg JU, Wolburg H, Horn LC, Dorschner W. Smooth muscle cells from human urinary bladder express connexin 43 in vivo and in vitro. World J Urol. 2002;20(4):250-4. doi: 10.1007/s00345-002-0289-9. [PubMed: 12215856].
  • 37. Haefliger JA, Tissieres P, Tawadros T, Formenton A, Beny JL, Nicod P, et al. Connexins 43 and 26 are differentially increased after rat bladder outlet obstruction. Exp Cell Res. 2002;274(2):216-25. doi: 10.1006/excr.2001.5465. [PubMed: 11900482].
  • 38. Sui GP, Rothery S, Dupont E, Fry CH, Severs NJ. Gap junctions and connexin expression in human suburothelial interstitial cells. BJU Int. 2002;90(1):118-29. [PubMed: 12081783].
  • 39. Ikeda Y, Fry C, Hayashi F, Stolz D, Griffiths D, Kanai A. Role of gap junctions in spontaneous activity of the rat bladder. Am J Physiol Renal Physiol. 2007;293(4):F1018-25. doi: 10.1152/ajprenal.00183.2007. [PubMed: 17581924].
  • 40. Haferkamp A, Mundhenk J, Bastian PJ, Reitz A, Dorsam J, Pannek J, et al. Increased expression of connexin 43 in the overactive neurogenic detrusor. Eur Urol. 2004;46(6):799-805. doi: 10.1016/j.eururo.2004.08.020. [PubMed: 15548450].
  • 41. Okada S, Kojima Y, Hamamoto S, Mizuno K, Sasaki S, Kohri K. Dietary soy isoflavone replacement improves detrusor overactivity of ovariectomized rats with altered connexin-43 expression in the urinary bladder. BJU Int. 2009;103(10):1429-35. [PubMed: 19462485].
  • 42. Hong SK, Yang JH, Kim TB, Kim SW, Paick JS. Effects of ovariectomy and oestrogen replacement on the function and expression of Rho-kinase in rat bladder smooth muscle. BJU Int. 2006;98(5):1114-7. doi: 10.1111/j.1464-410X.2006.06486.x. [PubMed: 17034613].
  • 43. Ouslander JG. Management of overactive bladder. N Engl J Med. 2004;350(8):786-99. doi: 10.1056/NEJMra032662. [PubMed: 14973214].
  • 44. Carley ME, Cliby WA, Spelsberg TC. P2X(3) receptor subunit messenger RNA expression in the female mouse bladder after oophorectomy with or without estrogen replacement. Am J Obstet Gynecol. 2002;187(1):103-6. [PubMed: 12114896].
  • 45. Samsioe G, Jansson I, Mellström D, Svanborg A. Occurrence, nature and treatment of urinary incontinence in a 70-year-old female population. Maturit. 1985;7(4):335-42.
  • 46. Grady D, Brown JS, Vittinghoff E, Applegate W, Varner E, Snyder T. Postmenopausal hormones and incontinence: the heart and estrogen/progestin replacement study. Obstet Gynecol. 2001;97(1):116-20.
  • 47. Hendrix SL, Cochrane BB, Nygaard IE, Handa VL, Barnabei VM, Iglesia C, et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA. 2005;293(8):935-48. doi: 10.1001/jama.293.8.935. [PubMed: 15728164].
  • 48. Grodstein F, Lifford K, Resnick NM, Curhan GC. Postmenopausal hormone therapy and risk of developing urinary incontinence. Obstet Gynecol. 2004;103(2):254-60. doi: 10.1097/01.AOG.0000107290.33034.6f. [PubMed: 14754692].
  • 49. Shapiro S, de Villiers TJ, Pines A, Sturdee DW, Baber RJ, Panay N, et al. Risks and benefits of hormone therapy: has medical dogma now been overturned?. Climacteric. 2014;17(3):215-22. doi: 10.3109/13697137.2014.905529. [PubMed: 24654673].
  • 50. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002;288(7):872-81. [PubMed: 12186605].
  • 51. Rufford J, Hextall A, Cardozo L, Khullar V. A double-blind placebo-controlled trial on the effects of 25 mg estradiol implants on the urge syndrome in postmenopausal women. Int Urogynecol J Pelvic Floor Dysfunct. 2003;14(2):78-83. doi: 10.1007/s00192-003-1054-3. [PubMed: 12851747].
  • 52. Robinson D, Cardozo LD. The role of estrogens in female lower urinary tract dysfunction. Urol. 2003;62(4):45-51.
  • 53. Cardozo L, Lose G, McClish D, Versi E. A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. Acta Obstet Gynecol Scand. 2004;83(10):892-7. doi: 10.1111/j.0001-6349.2004.00581.x. [PubMed: 15453881].
  • 54. Šimunić V, Banović I, Ciglar S, Jeren L, Pavičić Baldani D, Šprem M. Local estrogen treatment in patients with urogenital symptoms. Int J Gynecol Obstet. 2003;82(2):187-97.
  • 55. Nelken RS, Ozel BZ, Leegant AR, Felix JC, Mishell DJ. Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder. Menopause. 2011;18(9):962-6. doi: 10.1097/gme.0b013e3182104977. [PubMed: 21532512].
  • 56. Tseng LH, Wang AC, Chang YL, Soong YK, Lloyd LK, Ko YJ. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome. Neurourol Urodyn. 2009;28(1):47-51. doi: 10.1002/nau.20583. [PubMed: 19089890].
  • 57. Serati M, Salvatore S, Uccella S, Cardozo L, Bolis P. Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity?. Eur Urol. 2009;55(3):713-9. doi: 10.1016/j.eururo.2008.06.051. [PubMed: 18584946].
  • 58. Chughtai B, Forde JC, Buck J, Asfaw T, Lee R, Te AE, et al. The concomitant use of fesoterodine and topical vaginal estrogen in the management of overactive bladder and sexual dysfunction in postmenopausal women. Post Reprod Health. 2016;22(1):34-40. doi: 10.1177/2053369116633017. [PubMed: 26883688].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments